Viatris receives FDA approval for generic Sandostatin plus 3 other milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Viatris Provides Pipeline Update on Four Regulatory Milestones
December 18, 2025 6:59 AM ESTReceives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension)U.S. FDA Accepts New Drug Application for Low Dose Estrogen Weekly Patch for ContraceptionU.S. FDA Clears Investigational New Drug Application for MR-146 in Neurotrophic KeratopathyJapan Pharmaceuticals and Medical Devices Agency Accepts Japanese New Drug Application Filing for Pitolisant in Obstructive Sleep Apnea... More
